In terms of geographical markets, North America was the most sizeable region within the renin-angiotensin-system RAS-acting agents market in 2024. Asia-Pacific is forecasted to be the fastest ...

Review Series Published: 18 October 2012 Brain renin–angiotensin system in the nexus of hypertension and aging Amy C Arnold, Patricia E Gallagher & Debra I Diz Hypertension Research 36, 5–13 ...

Circulating renin–angiotensin system (RAS) activation is maintained after renal function has deteriorated. The activation of the intrarenal RAS plays a critical role in the pathophysiology of ...

Inhibition of the Renin-Angiotensin System and Vascular Protection Nikos Werner, MD, Michael Böhm, MD Disclosures Cardiovasc Rev Rep. 2003;24 (4) Modulation of the RAS Beyond ACE Inhibition ...

“Whether renin-angiotensin system (RAS) inhibition is safe and effective in patients with advanced CKD is unknown,” Edouard L. Fu, BSc, of Leiden University Medical Center, and colleagues wrote.

Renin-angiotensin system blockade conferred similar mortality benefits for Black vs. non-Black patients with HF, and despite less benefit for hospitalization for Black patients, absolute benefit ...

An alternative view suggests that virus-induced upregulation of the renin-angiotensin system (RAS) — a hormonal network that regulates blood pressure fluid, and electrolytes — accounts for the ...

In patients with diabetes, renin angiotensin system (RAS) blockers perform similarly to other antihypertensive medications, according to a study published in BMJ. Current recommendations offer ...

-- The European Medicines Agency said last week that it was initiating a review of the combined use of agents that block the renin-angiotensin system (RAS). The three classes of RAS-blocking drugs ...

Ditching renin-angiotensin system (RAS) inhibitors in advanced chronic kidney disease (CKD) didn't help to slow kidney decline, according to the STOP ACEi trial. Among patients with a baseline ...

"Previous studies have shown that use of RAS [renin-angiotensin-system] agents in heart failure can harm the kidneys, while neprilysin inhibitors had their share of safety concerns." ...

Prescription of a renin-angiotensin system (RAS) inhibitor following TAVR is associated with lower risks of mortality and hospitalization for heart failure at 1 year, especially in patients with ...